U.S., Feb. 5 -- ClinicalTrials.gov registry received information related to the study (NCT06806813) titled 'Italian Anderson Fabry Disease Cardiovascular Registry' on Jan. 09.
Brief Summary: The RICMAF Study is an observational, multicenter, non-pharmacological study conducted in Italy.
Although Anderson-Fabry Disease (AFD) is rare, it is likely underdiagnosed due to its nonspecific symptoms, leading to delays in proper treatment. The RICMAF Study aims to improve understanding of AFD, especially its cardiac manifestations, which are a major cause of mortality. By gathering data from a large, nationwide patient registry, this study seeks to answer key questions about AFD's clinical course and improve patient outcomes.
The primary goals of...